|
LEUKEMIA
|
| Chronic Myelogenous Leukemia (CML) |
ECOG S0325: Imatinib at 400 mg / day versus Imatinib at 800 mg/day |
| Chronic Lymphocytic Leukemia (CLL)-Previously treated, relapsed or refractory |
CTSU C10501: Asymptomatic individuals-- early intervention with Rituximab and Fludarabine versus observation with later intervention with Rituximab and Fludarabine
ECOG 10404: Three Fludarabine / antibody combination
ECOG E2903: Pentostatin, Cytoxan and Rituximab follwed by Campath-1H
|
| Acute Promyelocytic Leukemia |
CTSU S0521: Maintenace versus Observation for patients with previously untreated low and intermediate risk
CTSU S0535: ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin with previously untreated high risk |
Acute Lymphoblastic Leukemia (ALL) |
Refractory or Relapsed--ECOG E1904: Methotrexate, Vincristine, L-asparaginase & Dexamethasone (MOAD) with Campath
|
| Large Granular Lymphocytic Leukemia |
ECOG E5998: Initial treatment with Methotrexate |
| Hairy Cell Leukemia |
None |
| Acute Myeloid Leukemia (AML)
2nd or subsequent remission / Remission after primary induction failure
|
CTSU C10603: Induction threatment with Daunorubicin, Cytarabine, then consolidation with high dose Cytarabine plus Midostaurin or placebo (Individuals under the age of 60)
CTSU S0106: Addition of Gemtuzumab Ozogamicin (Mylotarg) induction treatment versus standard induction with Daunomycin & Ara-C followed by consolidation & subsequent treatment with Mylotarg or no additional treatment for patients younger than 56 yrs old with previously untreated de novo AML
ECOG E2902: Farnesyl Transferase Inhibitor (R115777)
|
| Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (Dysplastic Type), and Acute Myeloid Leukemia with multilineage Dysplasia |
ECOG E1905: Asacitidine with or withour MS-275 (Histone Deacetylase Inhibitor--Suspended 9/07 |
Refractory Idiopathic Thrombocytopenia Purpura (ITP |
Amgen 2000213: AMG 531 for severely refractory thrombocytopenic individuals with ITP - previosly treated with AMG 531
|
AVIDA--Vidaza Patient Registry for MDS and other Hematologic disorders |
|
LYMPHOMA
|
Low Grade Non-Hodgkin's Lymphoma (NHL)
Follicular grade 1 or 2, MALT, Small Lymphocytic Marginal Zone (nodal or splenic) |
NONE |
| Moderately Aggressive Non – Hodgkin's Lymphoma |
NONE
|
| Unfavorable Lymphoma (Diffuse Mixed, Diffuse Large Cell) |
NONE |
| Aggressive B-Cell NLH (Diffuse Large B-Cell is OK) | MDA 2004-0305: Rituximab plus CHOP (Cytoxan / Adriamycin / Oncovin / Predinose) with pegylated liposomal Doxorubicin--Must be more than 60 years of age
ECOG E3404: Response adapted therapy based on early FDG-PET scanning
|
| Angioimmunoblastic T-Cell; recurrent or relapsed disease |
ECOG E2402: Cyclosporine--must have measurable disease and prior chemotherapy, auto-transplant or steroid treatment failed |
| Peripheral T-Cell or Natural Killer Cell |
ECOG E2404: Bevacizumab + CHOP (Cytoxan / Adriamycin / Oncovin / Predinose) |
| DeNovo CD20 Diffuse Large B Cell--Stage II, III, IV and Stage I primary Mediastinal (Thymic) | CTSU C50303: R-CHOP (Rituximab plus CHOP [Cytoxan / Adriamycin / Oncovin / Predinose]) versus EPOCH-R ([VP-16 / Prednisone / Oncovin / Cytoxan / Adriamycin] plus Rituximab) |
| Diffuse Large Cell Stage I/II CD20+ |
NONE |
| Hodgkin's Lymphoma |
NONE |
| Mantle Cell Lymphoma |
NONE
|
|
MULTIPLE MYELOMA
|
| Initial diagnosis |
ECOG E1A06: Melphalan + Prednisone + Thalidomide versus Melphalan + Prednisone ++ Lenalidomide
CTSU S0777: CC-5013 (Lenalidomide) and low dose Dexamethasone versus Bortizomib, Lenalidomide and low dose Dexamethasone |
| Consolidation Treatment |
ECOG E1A05: Bortezomib + Lenalidomide + Dexamethasone versus Bortezomib + Dexamethasone for patient who completed Dexamethasone-based induction regimen |
Breast Cancer Clinic
